These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 24526358)

  • 21. Visual and whole-body quantitative analyses of
    Hotta M; Sonni I; Thin P; Nguyen K; Gardner L; Ciuca L; Hayrapetian A; Lewis M; Lubin D; Allen-Auerbach M
    Ann Nucl Med; 2024 Apr; 38(4):296-304. PubMed ID: 38252228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.
    Kumar R; Sharma P; Garg P; Karunanithi S; Naswa N; Sharma R; Thulkar S; Lata S; Malhotra A
    Eur Radiol; 2011 Nov; 21(11):2408-16. PubMed ID: 21750886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
    Kroiss A; Putzer D; Decristoforo C; Uprimny C; Warwitz B; Nilica B; Gabriel M; Kendler D; Waitz D; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
    Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitivity Comparison of
    Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography.
    Farchione A; Rufini V; Brizi MG; Iacovazzo D; Larghi A; Massara RM; Petrone G; Poscia A; Treglia G; De Marinis L; Giordano A; Rindi G; Bonomo L
    Pancreas; 2016 Mar; 45(3):345-54. PubMed ID: 26418904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.
    Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA
    Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
    Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
    Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
    Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.
    Graf J; Pape UF; Jann H; Denecke T; Arsenic R; Brenner W; Pavel M; Prasad V
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):881-894. PubMed ID: 31414209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study.
    Thuillier P; Maajem M; Schick U; Blanc-Beguin F; Hennebicq S; Metges JP; Salaun PY; Kerlan V; Bourhis D; Abgral R
    Clin Nucl Med; 2021 Feb; 46(2):111-118. PubMed ID: 33234927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammation-Based Index and
    Pauwels E; Van Binnebeek S; Vandecaveye V; Baete K; Vanbilloen H; Koole M; Mottaghy FM; Haustermans K; Clement PM; Nackaerts K; Van Cutsem E; Verslype C; Deroose CM
    J Nucl Med; 2020 Jul; 61(7):1014-1020. PubMed ID: 31806775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors.
    Weber M; Kessler L; Schaarschmidt B; Fendler WP; Lahner H; Antoch G; Umutlu L; Herrmann K; Rischpler C
    Nucl Med Commun; 2020 Apr; 41(4):363-369. PubMed ID: 31977752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification in (68)Ga-DOTA(0)-Phe(1)-Tyr(3)-octreotide positron emission tomography/computed tomography: can we be impartial about partial volume effects?
    Ruf J; Schiefer J; Kropf S; Furth C; Ulrich G; Kosiek O; Denecke T; Pavel M; Pascher A; Wiedenmann B; Amthauer H
    Neuroendocrinology; 2013; 97(4):369-74. PubMed ID: 23486004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
    Boursier C; Zaragori T; Bros M; Bordonne M; Melki S; Taillandier L; Blonski M; Roch V; Marie PY; Karcher G; Imbert L; Verger A
    Eur Radiol; 2023 Oct; 33(10):7089-7098. PubMed ID: 37148355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Tumor Burden on Quantitative [
    Werner RA; Hänscheid H; Leal JP; Javadi MS; Higuchi T; Lodge MA; Buck AK; Pomper MG; Lapa C; Rowe SP
    Mol Imaging Biol; 2019 Aug; 21(4):790-798. PubMed ID: 30406512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
    Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP
    AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.